ADVFN - Advanced Financial Network.
HOME» NASDAQ » A » ACOR Stock Price » ACOR Stock News

Acorda Therapeutics Share News

 Acorda Therapeutics (mm) Stock Price
ACOR Stock Price
 Acorda Therapeutics (mm) Stock Chart
ACOR Stock Chart
 Acorda Therapeutics (mm) Stock News
ACOR Stock News
 Acorda Therapeutics (mm) Company Information
ACOR Company Information
 Acorda Therapeutics (mm) Stock Trades
ACOR Stock Trades

Biogen Gets Letter Of Deficiency From Health Canada On Fampridine

By Thomas Gryta Of DOW JONES NEWSWIRES NEW YORK -(Dow Jones)- Biogen Idec Inc. (BIIB) has received a letter of deficiency from Health Canada for its application to sell the multiple sclerosis treatment fampridine in the country. The Weston, Mass., biotech company also recently received questions from the European Medicines Agency on an application to sell the same drug in the region. Biogen expects a decision later this month. The disclosures were made at the JPMorgan healthcare conference in San Francisco Tuesday by Chief Executive George Scangos. Scangos declined to comment on the letter or provide any further detail about the questions from the regulators. Fampridine helps improve walking in multiple sclerosis patients and is sold in the U.S. by Acorda Therapeutics Inc. (ACOR) under the name Ampyra. Separately, the company said that about 56,000 patients are using its MS drug Tysabri as of the end of December, an increase of 1,700 patients from fourth quarter and down from the 2,100 patients added in the third quarter. -By Thomas Gryta, Dow Jones Newswires; 212-416-2169;

Stock News for Acorda Therapeutics (ACOR)
04/14/201409:50:25Hot Stocks: Hot Stocks to Watch
11/15/201309:01:37HBK Investments LP 3Q 13F: Largest Eliminations
11/15/201309:01:27HBK Investments LP 3Q 13F: Largest Purchases
11/15/201309:01:27HBK Investments LP 3Q 13F: Largest Sales
11/15/201309:01:27HBK Investments LP 3Q 13F: Largest Eliminations -2-
10/29/201214:50:35Correction to 2nd Update on Companies Postponing Earnings Reports
10/29/201208:29:09Companies Postpone Earnings Reports in Light of Hurricane Sandy
10/02/201207:40:13PetSmart to Replace Sunoco in S&P 500
01/09/201209:07:39US Stock Futures: HOT STOCKS TO WATCH
07/25/201111:44:10Biogen, Acorda MS Drug Gets Conditional European Approval
07/01/201108:27:01Acorda To Pay Up To $35 Million To Medtronic In Licensing Deal
01/11/201120:23:15Biogen Gets Letter Of Deficiency From Health Canada On Fampridine
12/30/201017:22:24Approvals Of New Drugs Down In 2010 Vs 2009, 2008
12/09/201011:07:09Biogen CEO Expects To Make Biotech Generics As Market Develops
10/12/201015:20:08Acorda MS Drug To Get Improved Reimbursement From UnitedHealth
08/04/201017:55:05CORRECT: Acorda Shares Up As MS Drug Ampyra Shows Early Strength...
08/03/201013:26:06Acorda Shares Up As MS Drug Ampyra Shows Early Strength In 2Q
01/22/201016:28:14FDA OKs Ampyra To Improve Walking In Adults With Multiple Sclerosis

Acorda Therapeutics and other NASDAQ stock quotes are delayed by at least 20 minutes.
All other stock price and quote data is delayed by at least 15 minutes unless otherwise stated. By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations